FUSN insider filings

Fusion Pharmaceuticals Inc. — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2024-06-04. Screen FUSN transaction legs live →

Insider transaction summary — last 90 days

No insider filings (Forms 3/4/5) for FUSN between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.

Recent insider filings — Fusion Pharmaceuticals Inc.

FiledFormInsiderReported transactionsSource
2024-06-044Bitetti Teresa Marie — DirectorDisposition to issuer (D): 34,000 (derivative)EDGAR
2024-06-044Valliant John — Chief Executive Officer, DirectorDisposition to issuer (D): 318,147 · Disposition to issuer (D): 533,095 (derivative) · Disposition to issuer (D): 270,300 (derivative) · Disposition to issuer (D): 606,721 (derivative) · Disposition to issuer (D): 173,528 (derivative) · Disposition to issuer (D): 206,541 (derivative) · +6 moreEDGAR
2024-06-044Lee Philina — DirectorDisposition to issuer (D): 30,000 (derivative) · Disposition to issuer (D): 17,000 (derivative) · Disposition to issuer (D): 17,000 (derivative) · Disposition to issuer (D): 17,000 (derivative)EDGAR
2024-06-044Rawat Mohit — President & CBODisposition to issuer (D): 21,699 · Disposition to issuer (D): 257,000 (derivative) · Disposition to issuer (D): 77,900 (derivative) · Disposition to issuer (D): 300,000 (derivative) · Disposition to issuer (D): 135,500 (derivative) · Disposition to issuer (D): 81,300 (derivative)EDGAR
2024-06-044Bobilev Dmitri — Chief Medical OfficerDisposition to issuer (D): 550,000 (derivative) · Disposition to issuer (D): 151,700 (derivative) · Disposition to issuer (D): 91,000 (derivative)EDGAR
2024-06-044Bender Jeremy — DirectorDisposition to issuer (D): 34,000 (derivative)EDGAR
2024-06-044Burak Eric — Chief Technology OfficerDisposition to issuer (D): 38,490 · Disposition to issuer (D): 159,928 (derivative) · Disposition to issuer (D): 81,090 (derivative) · Disposition to issuer (D): 72,340 (derivative) · Disposition to issuer (D): 38,561 (derivative) · Disposition to issuer (D): 44,754 (derivative) · +9 moreEDGAR
2024-06-044Bergstrom Donald A — DirectorDisposition to issuer (D): 34,000 (derivative) · Disposition to issuer (D): 17,000 (derivative) · Disposition to issuer (D): 17,000 (derivative) · Disposition to issuer (D): 17,000 (derivative)EDGAR
2024-06-044GANNON STEVEN — DirectorDisposition to issuer (D): 56,400 · Disposition to issuer (D): 141,011 (derivative) · Disposition to issuer (D): 30,000 (derivative) · Disposition to issuer (D): 17,000 (derivative) · Disposition to issuer (D): 17,000 (derivative) · Disposition to issuer (D): 17,000 (derivative)EDGAR
2024-06-044Crowley John J — Chief Financial OfficerDisposition to issuer (D): 10,410 · Disposition to issuer (D): 38,561 (derivative) · Disposition to issuer (D): 26,972 (derivative) · Disposition to issuer (D): 60,852 (derivative) · Disposition to issuer (D): 138,000 (derivative) · Disposition to issuer (D): 167,000 (derivative) · +4 moreEDGAR
2024-06-044Meek David D. — DirectorDisposition to issuer (D): 34,000 (derivative)EDGAR
2024-06-044Leamon Christopher P — Chief Scientific OfficerDisposition to issuer (D): 11,957 · Disposition to issuer (D): 218,000 (derivative) · Disposition to issuer (D): 250,000 (derivative) · Disposition to issuer (D): 106,100 (derivative) · Disposition to issuer (D): 63,700 (derivative)EDGAR
2024-06-044Duncan Barbara Gayle — DirectorDisposition to issuer (D): 30,000 (derivative) · Disposition to issuer (D): 17,000 (derivative) · Disposition to issuer (D): 17,000 (derivative) · Disposition to issuer (D): 17,000 (derivative)EDGAR
2024-06-044CAGNONI PABLO J — DirectorDisposition to issuer (D): 30,000 (derivative) · Disposition to issuer (D): 17,000 (derivative) · Disposition to issuer (D): 17,000 (derivative) · Disposition to issuer (D): 17,000 (derivative) · Disposition to issuer (D): 141,011 (derivative)EDGAR
2024-01-054Burak Eric — Chief Technology OfficerGrant/award (A): 106,100 (derivative) @ $0 · Grant/award (A): 63,700 (derivative) @ $0EDGAR
2024-01-054Rawat Mohit — President & CBOGrant/award (A): 12,843 · Grant/award (A): 135,500 (derivative) @ $0 · Grant/award (A): 81,300 (derivative) @ $0EDGAR
2024-01-054Bobilev Dmitri — Chief Medical OfficerGrant/award (A): 151,700 (derivative) @ $0 · Grant/award (A): 91,000 (derivative) @ $0EDGAR
2024-01-054Valliant John — Chief Executive Officer, DirectorGrant/award (A): 320,400 (derivative) @ $0 · Grant/award (A): 192,200 (derivative) @ $0EDGAR
2024-01-054Crowley John J — Chief Financial OfficerGrant/award (A): 106,100 (derivative) @ $0 · Grant/award (A): 63,700 (derivative) @ $0EDGAR
2024-01-054Leamon Christopher P — Chief Scientific OfficerGrant/award (A): 11,957 · Grant/award (A): 106,100 (derivative) @ $0 · Grant/award (A): 63,700 (derivative) @ $0EDGAR
2023-10-164Bitetti Teresa Marie — DirectorGrant/award (A): 34,000 (derivative) @ $0EDGAR
2023-10-164Bender Jeremy — DirectorGrant/award (A): 34,000 (derivative) @ $0EDGAR
2023-10-164Meek David D. — DirectorGrant/award (A): 34,000 (derivative) @ $0EDGAR
2023-06-144Lee Philina — DirectorGrant/award (A): 17,000 (derivative) @ $0EDGAR
2023-06-144Bergstrom Donald A — DirectorGrant/award (A): 17,000 (derivative) @ $0EDGAR
2023-06-144GANNON STEVEN — DirectorGrant/award (A): 17,000 (derivative) @ $0EDGAR
2023-06-144Khuong Chau Quang — DirectorGrant/award (A): 17,000 (derivative) @ $0EDGAR
2023-06-144Preston Heather — DirectorGrant/award (A): 17,000 (derivative) @ $0EDGAR
2023-06-144Duncan Barbara Gayle — DirectorGrant/award (A): 17,000 (derivative) @ $0EDGAR
2023-06-144CAGNONI PABLO J — DirectorGrant/award (A): 17,000 (derivative) @ $0EDGAR
2023-01-094Valliant John — Chief Executive Officer, DirectorGrant/award (A): 500,000 (derivative) @ $0EDGAR
2023-01-094Rawat Mohit — President and CBOGrant/award (A): 300,000 (derivative) @ $0EDGAR
2023-01-094Burak Eric — Chief Technology OfficerGrant/award (A): 250,000 (derivative) @ $0EDGAR
2023-01-094Crowley John J — Chief Financial OfficerGrant/award (A): 250,000 (derivative) @ $0EDGAR
2023-01-094Leamon Christopher P — Chief Scientific OfficerGrant/award (A): 250,000 (derivative) @ $0EDGAR
2022-11-144Khuong Chau Quang — DirectorGrant/award (A): 42,093 @ $2.38EDGAR
2022-11-074Bobilev Dmitri — Chief Medical OfficerGrant/award (A): 550,000 (derivative) @ $0EDGAR
2022-08-114GANNON STEVEN — DirectorPurchase (P): 44,400 @ $2.03EDGAR
2022-06-224Lee Philina — DirectorGrant/award (A): 17,000 (derivative) @ $0EDGAR
2022-06-224Bergstrom Donald A — DirectorGrant/award (A): 17,000 (derivative) @ $0EDGAR
2022-06-224GANNON STEVEN — DirectorGrant/award (A): 17,000 (derivative) @ $0EDGAR
2022-06-224Khuong Chau Quang — DirectorGrant/award (A): 17,000 (derivative) @ $0EDGAR
2022-06-224Preston Heather — DirectorGrant/award (A): 17,000 (derivative) @ $0EDGAR
2022-06-224Duncan Barbara Gayle — DirectorGrant/award (A): 17,000 (derivative) @ $0EDGAR
2022-06-224CAGNONI PABLO J — DirectorGrant/award (A): 17,000 (derivative) @ $0EDGAR
2022-04-274Valliant John — Chief Executive Officer, DirectorSale (S): 2,036 @ $6.03 · Sale (S): 2,147 @ $6.07 · Sale (S): 4,511 @ $6.03EDGAR
2022-04-224Valliant John — Chief Executive Officer, DirectorSale (S): 367 @ $6.02 · Sale (S): 922 @ $6.01EDGAR
2022-04-134Valliant John — Chief Executive Officer, DirectorSale (S): 2,600 @ $7.37 · Sale (S): 18,255 @ $7.10 · Sale (S): 11,994 @ $6.41EDGAR
2022-04-084Valliant John — Chief Executive Officer, DirectorSale (S): 100 @ $7.58 · Sale (S): 1,255 @ $7.56 · Sale (S): 826 @ $7.52EDGAR
2022-04-054Valliant John — Chief Executive Officer, DirectorSale (S): 1,000 @ $7.75 · Sale (S): 700 @ $7.81 · Sale (S): 2,100 @ $7.67EDGAR

Recent 8-K events — Fusion Pharmaceuticals Inc.

Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →

FiledFormItems reportedSource
2024-06-048-K2.01 — Completion of Acquisition or Disposition of Assets
3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
3.03 — Material Modification to Rights of Security Holders
5.01 — Changes in Control of Registrant
5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2024-05-318-K8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2024-05-298-K5.07 — Submission of Matters to a Vote of Security Holders
7.01 — Regulation FD Disclosure
9.01 — Financial Statements and Exhibits
EDGAR
2024-05-108-K8.01 — Other EventsEDGAR
2024-05-078-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
2024-05-028-K8.01 — Other EventsEDGAR
2024-04-238-K8.01 — Other EventsEDGAR
2024-04-128-K/A8.01 — Other EventsEDGAR
2024-04-098-K8.01 — Other EventsEDGAR
2024-03-208-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?ticker=FUSN returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs